Net Asset Value and Portfolio Update
Net Asset Value
The Law Debenture Corporation p.l.c. announces that its Net Asset Value ("NAV") with borrowings at par and including fair value of IPS business on 31 August 2019 was 652.59 pence per share (ex income) and 668.11 pence per share (cum income), which excludes the 2019 interim dividend of 6.6p. With the Corporation's long term debt stated at fair value, the NAV was 618.05 pence per share (ex income) and 633.57 pence per share (cum income). The mid-market price at the close of business on 31 August 2019 was 566.00 pence per share. The interim dividend will be paid on 6 September 2019 to holders on the register at the record date of 9 August 2019.
In accordance with listing rule 15.6.8, The Law Debenture Corporation p.l.c. announces that it has no investments in other UK listed investment companies that require to be disclosed. Its top ten holdings, including all holdings with a value greater than 5% of the Corporation's gross assets as at 31 August 2019 are set out below.
Top 10 Holdings
The top 10 holdings in the investment portfolio as at 31 August 2019 were:
Rank | Name of Holding | % of portfolio (excl. cash) |
1. | Royal Dutch Shell | 3.82 |
2. | GlaxoSmithKline | 3.47 |
3. | BP | 2.16 |
4. | HSBC | 2.11 |
5. | Rio Tinto | 2.10 |
6. | Relx | 1.99 |
7. | Johnson Service | 1.97 |
8. | AstraZeneca | 1.77 |
9. | Prudential | 1.73 |
10. | Rolls Royce | 1.72 |
Geographical Split of investment portfolio
Region | % of portfolio |
UK | 70 |
Europe | 8 |
North America | 8 |
Japan | 1 |
Other Pacific | 2 |
Other | 1 |
Cash and Fixed Interest | 10 |
TOTAL | 100 |
Released by The Law Debenture Corporation p.l.c., Fifth Floor, 100 Wood Street, London, EC2V 7EX (contact Ian Bowden, Company Secretariat, 020 7696 5285).
The Law Debenture Corporation p.l.c. LEI number - 2138006E39QX7XV6PP21
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.